RegisterLogin

KRC-108

CAT: 0804-HY-123237Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-123237Size:1 Each
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
KRC-108, an aminopyridine, is an orally active multiple kinase inhibitor with IC50s of 80 nM, 23 nM, 3 nM, 70 nM, 30 nM, 39 nM for c-Met, c-Met M1250T, c-Met Y1230D, Ron, Flt3 and TrkA, respectively. KRC-108 induces cell cycle arrest, apoptotic cell death, and autophagy. KRC-108 exhibits anti-tumor activity in vivo in HT29 colorectal cancer, NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice[1].
CAS Number
[1146944-35-5]
UNSPSC
12352005
Target
Apoptosis; Autophagy; c-Met/HGFR; FLT3; Trk Receptor
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/krc-108.html
Smiles
NC1=NC=C(C=C1C2=NC3=CC=CC=C3O2)C4=CN(N=C4)C5CCNCC5
Molecular Formula
C20H20N6O
Molecular Weight
360.41
References & Citations
[1]Sun-Young Han, et al. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo. Invest New Drugs. 2012 Apr;30 (2) :518-23.|[2]Hyo Jeong Lee, et al. Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects. Biomol Ther (Seoul) . 2022 Jul 1;30 (4) :360-367.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Met; TrkA

Related Products

CatalogName
HY-164411KRC-00715
HY-117869AFK-108
HY-158153EGFR-IN-108
HY-171793DN-108
HY-P11258UPG-108
HY-P990321-01AMG-108
HY-111184-01PIK-108
HY-P10765DTS-108
HY-W590849-01F1874-108
HY-W899002CRBN ligand-108

Alternative Products

CatalogName
MBS5813920KRC-108
T200380-01KRC-00715
M24934-01PIK-108
T33765-01NVX-108
MBS130663-01DBPR-108
MBS5824074F1874-108
sc-204235ARG 108
T23655-01AFK-108
abx282703-01RG-108
T202543-01TAS-108

Popular Products